Back to Search Start Over

Multicenter evaluation of rapid antimicrobial susceptibility testing by VITEKĀ®2 directly from positive blood culture.

Authors :
Paluch M
Lleres-Vadeboin M
Poupet H
Chanard E
Wilhelm N
Nadji S
Prots L
Bala Y
Zambardi G
Cattoen C
Source :
Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2023 Jul; Vol. 106 (3), pp. 115950. Date of Electronic Publication: 2023 Apr 05.
Publication Year :
2023

Abstract

Study Objective: To compare the antimicrobial susceptibility testing (AST) performance of positive blood cultures (PBC) VITEK®2 off-label use (D0) and traditional VITEK®2 workflow using isolated colonies after overnight (D1).<br />Methods: Patient samples with monomicrobial Gram-negative rod or Gram-positive cocci in clusters bacteremia were tested on D0 and compared to D1 AST results in 7 laboratories in France.<br />Results: Overall, categorical and essential agreement rates were 98.4% and 96.7%, respectively. Very major discrepancy and major discrepancy rates for Enterobacterales and Staphylococci satisfied the NF EN ISO 20776-2 (2007) criteria for sepsis-relevant drugs. Very major discrepancies were >3% for amoxicillin-clavulanate (4.9%, 6/122), piperacillin-tazobactam (7.5%, 4/53) and meropenem (33%,1/3) for Enterobacterales and gentamicin for Staphylococci (4.6%, 4/87).<br />Conclusion: Direct AST from PBC broths by VITEK®2 for Enterobacterales and Staphylococci is reliable and fast and may positively influence antimicrobial stewardship.<br /> (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1879-0070
Volume :
106
Issue :
3
Database :
MEDLINE
Journal :
Diagnostic microbiology and infectious disease
Publication Type :
Academic Journal
Accession number :
37182374
Full Text :
https://doi.org/10.1016/j.diagmicrobio.2023.115950